Pricing Under The Spotlight As Novo Files Next-Generation Insulins
Novo Nordisk AS says it won’t seek the highest price it believes its next-generation insulins, the ultra-long-acting Degludec and Degludec Plus, could command on the basis of health economic data alone.
You may also be interested in...
FDA’s advisory committee meeting on Nov. 8 falls just after the already-extended user fee date for Novo Nordisk’s long-acting insulin degludec and degludec/insulin aspart.
Market-leader Novo is confident it can continue to innovate in insulin – and command premium prices
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country